As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

FRANKFURT, Nov 14 (Reuters) - Merck KGaA (MRCG.DE), opens new tab on Thursday reported a gain of 11.9% in adjusted quarterly ...

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

The life-sciences and chemical group said it now expects 2024 net sales in the lower half of its previously expected range of ...

Sales Numbers of Other Key MRK Products In vaccines ... products like Winrevair drove the company’s top line. Despite the encouraging results, Merck’s shares were down 3% in pre-market ...

Merck is a global healthcare company that develops and sells prescription medicines, vaccines, biologic therapies, and animal health products. With its $255 billion market cap Merck is the seventh ...

Merck, Fincantieri, Geox, Generali, Veon, Swiss Re, Burberry, Metro Bank, Aviva and Deutsche Telekom among those reporting ...

Although Merck does not provide specific product-level forecasts, CEO Rob Davis offered some perspective, anticipating Gardasil sales in China could reach around $2 billion to $3 billion in 2025.

Zentalis Pharmaceuticals (ZNTL) announced changes to its executive leadership team to support the Company as it plans and executes ...